Investment analysts at William Blair cut their Q1 2025 earnings per share (EPS) estimates for U.S. Physical Therapy in a ...

Equities research analysts at William Blair lowered their Q2 2026 earnings per share estimates for Zumiez in a report ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...

We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to Market Perform. Analyst Price Forecast Suggests 38.42% Upside As of March 4, ...

William Blair analyst Tim Mulrooney maintained a Hold rating on ABM Industries (ABM – Research Report) today. The company’s shares opened today ...

The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...

Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...